Our findings strongly indicate that dapagliflozin attenuated the prolongation of ventricular repolarization, regardless of body weight changes, potassium levels, estimated glomerular filtration rate, C-reactive protein, echocardiographic parameters and was consistent in the different subgroups predefined in the study, suggesting that the drug may benefit a wide variety of patients with T2DM. The gene discussed is CRP; the disease is type 2 diabetes mellitus.